Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Beda

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Tumori|November 28, 2007
When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?Manuela Beda, Umberto Basso, Cristina Ghiotto, et al.
Critical Reviews in Oncology/Hematology|February 5, 2008
Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology programUmberto Basso, Singora Tonti, Catia Bassi, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Tumori|November 28, 2007
When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?Manuela Beda, Umberto Basso, Cristina Ghiotto, et al.
Critical Reviews in Oncology/Hematology|February 5, 2008
Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology programUmberto Basso, Singora Tonti, Catia Bassi, et al.
Pageof 1